PLX

Business Context and Reporting Period

Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Protalix is a biopharmaceutical company in the development stage, focused on creating recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The lead product candidate is prGCD for the treatment of Gaucher disease, currently in a pivotal Phase III clinical trial. The company has no approved products and has not generated significant product revenue.

Key Financial Metrics

Liquidity: As of June 30, 2009, the company held $29.1 million in cash and cash equivalents. Management estimates these resources are sufficient to fund operations for approximately 18 months.

Material Changes vs. Prior Period

• Revenue: The company recorded $830,000 in revenue for the six months ended June 30, 2009, compared to no revenue in the prior year period. This is attributed to non-product sales revenue.
• Net Loss: Net loss increased by approximately 14% to $10.6 million for the six-month period compared to $9.3 million in the prior year.
• R&D Expenses: Increased by 17% ($1.6 million) year-over-year for the six-month period, primarily due to a $1.3 million increase in costs related to consultants and subcontractors for the Phase III clinical trial of prGCD. This was partially offset by an increase in government grants.
• G&A Expenses: Decreased by 40% ($1.6 million) year-over-year for the six-month period, driven mainly by a $1.0 million reduction in share-based compensation expenses.
• Cash Position: Cash and cash equivalents decreased by $13.5 million from the beginning of the period ($42.6 million) to $29.1 million, reflecting net cash outflows from operations and investing activities.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company expects to report results of its Phase III clinical trial for prGCD in the second half of 2009.
• Submission of a New Drug Application (NDA) to the FDA is anticipated in the fourth quarter of 2009.
• Management expects operating losses to continue and increase as the company advances clinical trials and prepares for potential commercialization.
• Additional financing will likely be required to fund future operations beyond the next 18 months.

Risks and Contingencies:

• Regulatory Risk: No assurance exists that the company will receive regulatory approval for prGCD or other candidates.
• Liquidity Risk: The company has an accumulated deficit of $85.6 million and relies on external financing to continue operations.
• Currency Risk: Approximately 35% of costs are incurred in New Israeli Shekels (NIS); devaluation of the USD against the NIS impacts financial results.
• Development Risk: Delays in clinical trials, patient enrollment, or rejection of applications could materially impact the business.

Key Facts for Investor Verification

• Cash Runway: Verify the 18-month liquidity estimate against current burn rates and potential unexpected cost increases.
• Clinical Trial Status: Confirm the timeline for the Phase III prGCD trial results and the subsequent NDA submission in late 2009.
• Revenue Source: Investigate the nature of the $830,000 revenue recorded, as the company has no approved commercial products.
• Capital Needs: Assess the likelihood and terms of future equity or debt financing required to sustain operations post-2010.
• Share-Based Compensation: Monitor the impact of stock option grants and vesting schedules on future G&A and R&D expenses.